<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26673324</PMID><DateCompleted><Year>2016</Year><Month>09</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>10</Issue><PubDate><Year>2015</Year><Month>Dec</Month><Day>15</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>Preventing the Androgen Receptor N/C Interaction Delays Disease Onset in a Mouse Model of SBMA.</ArticleTitle><Pagination><StartPage>2312</StartPage><EndPage>2323</EndPage><MedlinePgn>2312-23</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2015.11.019</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(15)01319-4</ELocationID><Abstract><AbstractText>Spinal and bulbar muscular atrophy (SBMA) is a neurodegenerative disease caused by a polyglutamine expansion in the androgen receptor (AR) and is associated with misfolding and aggregation of the mutant AR. We investigated the role of an interdomain interaction between the amino (N)-terminal FxxLF motif and carboxyl (C)-terminal AF-2 domain in a mouse model of SBMA. Male transgenic mice expressing polyQ-expanded AR with a mutation in the FxxLF motif (F23A) to prevent the N/C interaction displayed substantially improved motor function compared with N/C-intact AR-expressing mice and showed reduced pathological features of SBMA. Serine 16 phosphorylation was substantially enhanced by the F23A mutation; moreover, the protective effect of AR F23A was dependent on this phosphorylation. These results reveal an important role for the N/C interaction on disease onset in mice and suggest that targeting AR conformation could be a therapeutic strategy for patients with SBMA.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zboray</LastName><ForeName>Lori</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pluciennik</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Curtis</LastName><ForeName>Dana</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yuhong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berman-Booty</LastName><ForeName>Lisa D</ForeName><Initials>LD</Initials><AffiliationInfo><Affiliation>Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orr</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kesler</LastName><ForeName>Cristina T</ForeName><Initials>CT</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Genetics, University of Virginia Health System, Center for Cell Signaling, Charlottesville, VA&#xa0;22908, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berger</LastName><ForeName>Tamar</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gioeli</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Immunology and Cancer Biology, University of Virginia, Charlottesville, VA 22908, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paschal</LastName><ForeName>Bryce M</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Genetics, University of Virginia Health System, Center for Cell Signaling, Charlottesville, VA&#xa0;22908, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merry</LastName><ForeName>Diane E</ForeName><Initials>DE</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA. Electronic address: diane.merry@jefferson.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 CA178338</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS076919</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA214872</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS076919</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 CA104106</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>2P01CA104106</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31 NS077792</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 OD010463</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA044579</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>12</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011944">Receptors, Androgen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055534" MajorTopicYN="N">Bulbo-Spinal Atrophy, X-Linked</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047468" MajorTopicYN="N">Immunoprecipitation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011487" MajorTopicYN="N">Protein Conformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011944" MajorTopicYN="N">Receptors, Androgen</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>1</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>11</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26673324</ArticleId><ArticleId IdType="mid">NIHMS737090</ArticleId><ArticleId IdType="pmc">PMC4684905</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2015.11.019</ArticleId><ArticleId IdType="pii">S2211-1247(15)01319-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Banno H, Katsuno M, Suzuki K, Takeuchi Y, Kawashima M, Suga N, Takamori M, Ito M, Nakamura T, Matsuo K, et al. Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy. Ann Neurol. 2009;65:140&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pubmed">19259967</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt DR, Davis J, Fischer M, Lee MK, Slunt HH, Ratovitsky T, Regard J, Copeland NG, Jenkins NA, Sisodia SS, et al. A vector for expressing foreign genes in the brains and hearts of transgenic mice. Genet Anal. 1996;13:159&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pubmed">9117892</ArticleId></ArticleIdList></Reference><Reference><Citation>Brinkmann AO. Molecular basis of androgen insensitivity. Mol Cell Endocrinol. 2001;179:105&#x2013;109.</Citation><ArticleIdList><ArticleId IdType="pubmed">11420135</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks SP, Dunnett SB. Tests to assess motor phenotype in mice: a user&#x2019;s guide. Nat Rev Neurosci. 2009;10:519&#x2013;529.</Citation><ArticleIdList><ArticleId IdType="pubmed">19513088</ArticleId></ArticleIdList></Reference><Reference><Citation>Callewaert L, Verrijdt G, Christiaens V, Haelens A, Claessens F. Dual function of an amino-terminal amphipathic helix in androgen receptor-mediated transactivation through specific and nonspecific response elements. J Biol Chem. 2003;278:8212&#x2013;8218.</Citation><ArticleIdList><ArticleId IdType="pubmed">12509416</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen HK, Fernandez-Funez P, Acevedo SF, Lam YC, Kaytor MD, Fernandez MH, Aitken A, Skoulakis EM, Orr HT, Botas J, et al. Interaction of Akt-phosphorylated ataxin-1 with 14-3-3 mediates neurodegeneration in spinocerebellar ataxia type 1. Cell. 2003;113:457&#x2013;468.</Citation><ArticleIdList><ArticleId IdType="pubmed">12757707</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Feany MB. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat Neurosci. 2005;8:657&#x2013;663.</Citation><ArticleIdList><ArticleId IdType="pubmed">15834418</ArticleId></ArticleIdList></Reference><Reference><Citation>Chevalier-Larsen ES, O&#x2019;Brien CJ, Wang H, Jenkins SC, Holder L, Lieberman AP, Merry DE. Castration restores function and neurofilament alterations of aged symptomatic males in a transgenic mouse model of spinal and bulbar muscular atrophy. J Neurosci. 2004;24:4778&#x2013;4786.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729468</ArticleId><ArticleId IdType="pubmed">15152038</ArticleId></ArticleIdList></Reference><Reference><Citation>Chua JP, Reddy SL, Yu Z, Giorgetti E, Montie HL, Mukherjee S, Higgins J, McEachin RC, Robins DM, Merry DE, et al. Disrupting SUMOylation enhances transcriptional function and ameliorates polyglutamine androgen receptor-mediated disease. J Clin Invest. 2015;125:831&#x2013;845.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4319414</ArticleId><ArticleId IdType="pubmed">25607844</ArticleId></ArticleIdList></Reference><Reference><Citation>Doesburg P, Kuil CW, Berrevoets CA, Steketee K, Faber PW, Mulder E, Brinkmann AO, Trapman J. Functional in vivo interaction between the amino-terminal, transactivation domain and the ligand binding domain of the androgen receptor. Biochem. 1997;36:1052&#x2013;1064.</Citation><ArticleIdList><ArticleId IdType="pubmed">9033395</ArticleId></ArticleIdList></Reference><Reference><Citation>Duvick L, Barnes J, Ebner B, Agrawal S, Andresen M, Lim J, Giesler GJ, Zoghbi HY, Orr HT. SCA1-like disease in mice expressing wild-type ataxin-1 with a serine to aspartic acid replacement at residue 776. Neuron. 2010;67:929&#x2013;935.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2946945</ArticleId><ArticleId IdType="pubmed">20869591</ArticleId></ArticleIdList></Reference><Reference><Citation>Emamian ES, Kaytor MD, Duvick LA, Zu T, Tousey SK, Zoghbi HY, Clark HB, Orr HT. Serine 776 of ataxin-1 is critical for polyglutamine-induced disease in SCA1 transgenic mice. Neuron. 2003;38:375&#x2013;387.</Citation><ArticleIdList><ArticleId IdType="pubmed">12741986</ArticleId></ArticleIdList></Reference><Reference><Citation>Fargo KN, Alexander TD, Tanzer L, Poletti A, Jones KJ. Androgen regulates neuritin mRNA levels in an in vivo model of steroid-enhanced peripheral nerve regeneration. J Neurotrauma. 2008;25:561&#x2013;566.</Citation><ArticleIdList><ArticleId IdType="pubmed">18419250</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Rhodes LE, Kokkinis AD, White MJ, Watts CA, Auh S, Jeffries NO, Shrader JA, Lehky TJ, Li L, Ryder JE, et al. Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo-controlled trial. Lancet Neurol. 2011;10:140&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3056353</ArticleId><ArticleId IdType="pubmed">21216197</ArticleId></ArticleIdList></Reference><Reference><Citation>Gioeli D, Paschal BM. Post-translational modification of the androgen receptor. Mol Cell Endocrinol. 2012;352:70&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">21820033</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottlieb B, Beitel LK, Nadarajah A, Paliouras M, Trifiro M. The androgen receptor gene mutations database: 2012 update. Human mutation. 2012;33:887&#x2013;894.</Citation><ArticleIdList><ArticleId IdType="pubmed">22334387</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu X, Greiner ER, Mishra R, Kodali R, Osmand A, Finkbeiner S, Steffan JS, Thompson LM, Wetzel R, Yang XW. Serines 13 and 16 are critical determinants of full-length human mutant huntintin induced disease pathogenesis in HD mice. Neuron. 2009;64:828&#x2013;840.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2807408</ArticleId><ArticleId IdType="pubmed">20064390</ArticleId></ArticleIdList></Reference><Reference><Citation>Harding AE, Thomas PK, Baraitser M, Bradbury PG, Morgan-Hughes JA, Ponsford JR. X-linked recessive bulbospinal neuronopathy: report of ten cases. J Neurol Neurosurg Psych. 1982;45:1012&#x2013;1019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC491638</ArticleId><ArticleId IdType="pubmed">6890989</ArticleId></ArticleIdList></Reference><Reference><Citation>He B, Gampe RT, Jr, Kole AJ, Hnat AT, Stanley TB, An G, Stewart EL, Kalman RI, Minges JT, Wilson EM. Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance. Mol Cell. 2004;16:425&#x2013;438.</Citation><ArticleIdList><ArticleId IdType="pubmed">15525515</ArticleId></ArticleIdList></Reference><Reference><Citation>He B, Kemppainen J, Voegel J, Gronemeyer H, Wilson EM. Activation function 2 in the human androgen receptor ligand binding domain mediates interdomain communication with the NH(2)-terminal domain. J Biol Chem. 1999;274:37219&#x2013;37225.</Citation><ArticleIdList><ArticleId IdType="pubmed">10601285</ArticleId></ArticleIdList></Reference><Reference><Citation>He B, Kemppainen J, Wilson EM. FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor. J Biol Chem. 2000;275:22986&#x2013;22994.</Citation><ArticleIdList><ArticleId IdType="pubmed">10816582</ArticleId></ArticleIdList></Reference><Reference><Citation>He B, Lee LW, Minges JT, Wilson EM. Dependence of selective gene activation on the androgen receptor NH2- and COOH-terminal interaction. J Biol Chem. 2002;277:25631&#x2013;25639.</Citation><ArticleIdList><ArticleId IdType="pubmed">12000757</ArticleId></ArticleIdList></Reference><Reference><Citation>Heine EM, Berger TR, Pluciennik A, Orr CR, Zboray L, Merry DE. Proteasome-mediated proteolysis of the polyglutamine-expanded androgen receptor is a late event in spinal and bulbar muscular atrophy (SBMA) pathogenesis. J Biol Chem. 2015;290:12572&#x2013;12584.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4432278</ArticleId><ArticleId IdType="pubmed">25795778</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuno M, Adachi H, Kume A, Li M, Nakagomi Y, Niwa H, Sang C, Kobayashi Y, Doyu M, Sobue G. Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron. 2002;35:843&#x2013;854.</Citation><ArticleIdList><ArticleId IdType="pubmed">12372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuno M, Banno H, Suzuki K, Takeuchi Y, Kawashima M, Yabe I, Sasaki H, Aoki M, Morita M, Nakano I, et al. Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo, controlled trial. Lancet Neurol. 2010;9:875&#x2013;884.</Citation><ArticleIdList><ArticleId IdType="pubmed">20691641</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazmin D, Prytkova C, Cook E, Wolfinger R, Chu T-M, Beratan D, Norris JD, Chang C-y, McDonnell DP. Linking ligand-induced alterations in androgen receptor structure to differential gene expression: a first step in the rational design of selective androgen receptor modulators. Mol Endocrinol. 2006;20:1201&#x2013;1217.</Citation><ArticleIdList><ArticleId IdType="pubmed">16574741</ArticleId></ArticleIdList></Reference><Reference><Citation>La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature. 1991;353:77&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">2062380</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam YC, Bowman AB, Jafar-Nejad P, Lim J, Richman R, Fryer JD, Hyun ED, Duvick LA, Orr HT, Botas J, et al. ATAXIN-1 interacts with the repressor Capicua in its native complex to cause SCA1 neuropathology. Cell. 2006;127:1335&#x2013;1347.</Citation><ArticleIdList><ArticleId IdType="pubmed">17190598</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M, Miwa S, Kobayashi Y, Merry DE, Yamamoto M, Tanaka F, Doyu M, Hashizume Y, Fischbeck KH, Sobue G. Nuclear inclusions of the androgen receptor protein in spinal and bulbar muscular atrophy. Ann Neurol. 1998a;44:249&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">9708548</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M, Nakagomi Y, Kobayashi Y, Merry DE, Tanaka F, Doyu M, Mitsuma T, Hashizume Y, Fischbeck KH, Sobue G. Nonneural nuclear inclusions of androgen receptor protein in spinal and bulbar muscular atrophy. Am J Pathol. 1998b;153:695&#x2013;701.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1853004</ArticleId><ArticleId IdType="pubmed">9736019</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M, Sobue G, Doyu M, Mukai E, Hashizume Y, Mitsuma T. Primary sensory neurons in X-linked recessive bulbospinal neuropathy: histopathology and androgen receptor gene expression. Muscle Nerve. 1995;3:301&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">7870107</ArticleId></ArticleIdList></Reference><Reference><Citation>MacLean HE, Chiu WSM, Notini AJ, Axell A-M, Davey RA, McManus JF, Ma C, Plant DR, Lynch GS, Zajac JD. Impaired skeletal muscle development and function in male, but not female, genomic androgen receptor knockout mice. FASEB J. 2008;22:2676&#x2013;2689.</Citation><ArticleIdList><ArticleId IdType="pubmed">18390925</ArticleId></ArticleIdList></Reference><Reference><Citation>Marron TU, Guerini V, Rusmini P, Sau D, Brevini TA, Martini L, Poletti A. Androgen-induced neurite outgrowth is mediated by neuritin in motor neurones. J Neurochem. 2005;92:10&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">15606892</ArticleId></ArticleIdList></Reference><Reference><Citation>Milan G, Romanello V, Pescatore F, Armani A, Paik JH, Frasson L, Seydel A, Zhao J, Abraham R, Goldberg AL, et al. Regulation of autophagy and the ubiquitin-proteasome system by the FoxO transcriptional network during muscle atrophy. Nature communications. 2015;6:6670.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4403316</ArticleId><ArticleId IdType="pubmed">25858807</ArticleId></ArticleIdList></Reference><Reference><Citation>Mojsilovic-Petrovic J, Nedelsky N, Boccitto M, Mano I, Georgiades SN, Zhou W, Liu Y, Neve RL, Taylor JP, Driscoll M, et al. FOXO3a is broadly neuroprotective in vitro and in vivo against insults implicated in motor neuron diseases. J Neurosci. 2009;29:8236&#x2013;8247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2748231</ArticleId><ArticleId IdType="pubmed">19553463</ArticleId></ArticleIdList></Reference><Reference><Citation>Montie HL, Cho MS, Holder L, Liu Y, Tsvetkov AS, Finkbeiner S, Merry DE. Cytoplasmic retention of polyglutamine-expanded androgen receptor ameliorates disease via autophagy in a mouse model of spinal and bulbar muscular atrophy. Hum Mol Genet. 2009;18:1937&#x2013;1950.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2678926</ArticleId><ArticleId IdType="pubmed">19279159</ArticleId></ArticleIdList></Reference><Reference><Citation>Montie HL, Pestell RG, Merry DE. SIRT1 modulates aggregation and toxicity through deacetylation of the androgen receptor in cell models of SBMA. J Neurosci. 2011;31:17425&#x2013;17436.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6088793</ArticleId><ArticleId IdType="pubmed">22131404</ArticleId></ArticleIdList></Reference><Reference><Citation>Nedelsky NB, Pennuto M, Smith RB, Palazzolo I, Moore J, Nie Z, Neale G, Taylor JP. Native functions of the androgen receptor are essential to pathogenesis in a Drosophila model of spinal and bulbar muscular atrophy. Neuron. 2010;67:936&#x2013;952.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3514079</ArticleId><ArticleId IdType="pubmed">20869592</ArticleId></ArticleIdList></Reference><Reference><Citation>Orr CR, Montie HL, Liu Y, Bolzoni E, Jenkins SC, Wilson EM, Joseph JD, McDonnell DP, Merry DE. An interdomain interaction of the androgen receptor is required for its aggregation and toxicity in spinal and bulbar muscular atrophy. J Biol Chem. 2010;285:35567&#x2013;35577.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2975181</ArticleId><ArticleId IdType="pubmed">20826791</ArticleId></ArticleIdList></Reference><Reference><Citation>Oueslati A, Schneider BL, Aebischer P, Lashuel HA. Polo-like kinase 2 regulates selective autophagic alpha-synuclein clearance and suppresses its toxicity in vitro. Proc Natl Acad Sci U S A. 2013;110:E3945&#x2013;E3954.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3799334</ArticleId><ArticleId IdType="pubmed">23983262</ArticleId></ArticleIdList></Reference><Reference><Citation>Palazzolo I, Burnett BG, Young JE, Brenne PL, La Spada AR, Fischbeck KH, Howell BW, Pennuto M. Akt blocks ligand binding and protects against expanded polyglutamine androgen receptor toxicity. Hum Mol Genet. 2007;16:1593&#x2013;1603.</Citation><ArticleIdList><ArticleId IdType="pubmed">17470458</ArticleId></ArticleIdList></Reference><Reference><Citation>Palazzolo I, Stack C, Kong L, Musaro A, Adachi H, Katsuno M, Sobue G, Taylor JP, Sumner CJ, Fischbeck KH, et al. Overexpression of IGF-1 in muscle attenuates disease in a mouse model of spinal and bulbar muscular atrophy. Neuron. 2009;63:316&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2735765</ArticleId><ArticleId IdType="pubmed">19679072</ArticleId></ArticleIdList></Reference><Reference><Citation>Renier KJ, Troxell-Smith SM, Johansen JA, Katsuno M, Adachi H, Sobue G, Chua JP, Sun Kim H, Lieberman AP, Breedlove SM, et al. Antiandrogen flutamide protects male mice from androgen-dependent toxicity in three models of spinal bulbar muscular atrophy. Endocrinology. 2014;155:2624&#x2013;2634.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4060177</ArticleId><ArticleId IdType="pubmed">24742193</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhodes LE, Freeman BK, Auh S, Kokkinis AD, La Pean A, Chen C, Lehky TJ, Shrader JA, Levy EW, Harris-Love M, et al. Clinical features of spinal and bulbar muscular atrophy. Brain. 2009;132:3242&#x2013;3251.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2792370</ArticleId><ArticleId IdType="pubmed">19846582</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy J, Minotti S, Dong L, Figlewicz DA, Durham HD. Glutamate potentiates the toxicity of mutant Cu/Zn-superoxide dismutase in motor neurons by postsynaptic calcium-dependent mechanisms. J Neurosci. 1998;18:9673&#x2013;9684.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793286</ArticleId><ArticleId IdType="pubmed">9822728</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh R, Pervin S, Shryne J, Gorski R, Chaudhuri G. Castration increases and androgens decrease nitric oxide synthase activity in the brain: physiologic imiplications. Proc Natl Acad Sci U S A. 2000;97:3672&#x2013;3677.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC16298</ArticleId><ArticleId IdType="pubmed">10725371</ArticleId></ArticleIdList></Reference><Reference><Citation>Sobue G, Hashizume Y, Mukai E, Hirayama M, Mitsuma T, Takahashi A. X-linked recessive bulbospinal neuronopathy: a clinicopathological study. Brain. 1989;112:209&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">2917278</ArticleId></ArticleIdList></Reference><Reference><Citation>Soraru G, D&#x2019;Ascenzo C, Polo A, Palmieri A, Baggio L, Vergani L, Gellera C, Moretto G, Pegoraro E, Angelini C. Spinal and bulbar muscular atrophy: skeletal muscle pathology in male patients and heterozygous females. J Neurol Sci. 2008;264:100&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">17854832</ArticleId></ArticleIdList></Reference><Reference><Citation>Strickfaden SC, Winters MJ, Ben-Ari G, Lamson RE, Tyers M, Pryciak PM. A mechanism for cell-cycle regulation of MAP kinase signaling in a yeast differentiation pathway. Cell. 2007;128:519&#x2013;531.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1847584</ArticleId><ArticleId IdType="pubmed">17289571</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeyama K, Ito S, Yamamoto A, Tanimoto H, Furutani T, Kanuka H, Miura M, Tabata T, Kato S. Androgen-dependent neurodegeneration by polyglutamine-expanded human androgen receptor in Drosophila. Neuron. 2002;35:855&#x2013;864.</Citation><ArticleIdList><ArticleId IdType="pubmed">12372281</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson LM, Aiken CT, Kaltenbach LS, Agrawal N, Illes K, Khoshnan A, Martinez-Vincente M, Arrasate M, O&#x2019;Rourke JG, Khashwji H, et al. IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome. J Cell Biol. 2009;187:1083&#x2013;1099.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2806289</ArticleId><ArticleId IdType="pubmed">20026656</ArticleId></ArticleIdList></Reference><Reference><Citation>Walcott JL, Merry DE. Ligand promotes intranuclear inclusions in a novel cell model of spinal and bulbar muscular atrophy. J Biol Chem. 2002;277:50855&#x2013;50859.</Citation><ArticleIdList><ArticleId IdType="pubmed">12388541</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilde J, Moss T, Thrush D. X-linked bulbo-spinal neuronopathy: a family study of three patients. J Neurol Neurosurg Psychiatry. 1987;50:279&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1031791</ArticleId><ArticleId IdType="pubmed">3031222</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto T, Yokota K, AMao R, Maeno T, Haga N, Taguri M, Ohtsu H, Ichikawa Y, Goto J, Tsuji S. An open trial of long-term testosterone suppression in spinal and bulbar muscular atrophy. Muscle Nerve. 2013;47:816&#x2013;822.</Citation><ArticleIdList><ArticleId IdType="pubmed">23512333</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang CS, Xin HW, Kelley JB, Spencer A, Barautigan DL, Paschal BM. Ligand binding to the androgen receptor induces conformational changes that regulate phosphatase interactions. Mol Cell Biol. 2007;27:3390&#x2013;3404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1899975</ArticleId><ArticleId IdType="pubmed">17325038</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>